Baader Bank Aktiengesellschaft Purchases 16,852 Shares of Pfizer Inc. (NYSE:PFE)

Baader Bank Aktiengesellschaft raised its position in shares of Pfizer Inc. (NYSE:PFE) by 27.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 77,765 shares of the biopharmaceutical company’s stock after purchasing an additional 16,852 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Pfizer were worth $2,073,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in PFE. Savvy Advisors Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $557,000. Thornburg Investment Management Inc. boosted its position in shares of Pfizer by 0.9% during the fourth quarter. Thornburg Investment Management Inc. now owns 7,902,902 shares of the biopharmaceutical company’s stock valued at $227,525,000 after purchasing an additional 70,004 shares in the last quarter. CCLA Investment Management grew its stake in Pfizer by 14.1% in the fourth quarter. CCLA Investment Management now owns 44,615 shares of the biopharmaceutical company’s stock worth $1,284,000 after purchasing an additional 5,528 shares during the period. Janney Capital Management LLC raised its holdings in Pfizer by 10.8% in the fourth quarter. Janney Capital Management LLC now owns 459,934 shares of the biopharmaceutical company’s stock worth $13,242,000 after purchasing an additional 44,969 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Pfizer by 6.9% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,617,918 shares of the biopharmaceutical company’s stock valued at $167,021,000 after buying an additional 363,931 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.11 during mid-day trading on Thursday, reaching $28.93. The company’s stock had a trading volume of 40,061,284 shares, compared to its average volume of 43,043,617. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a fifty day moving average of $27.13 and a two-hundred day moving average of $28.04. The firm has a market capitalization of $163.93 billion, a PE ratio of -479.92, a P/E/G ratio of 1.20 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the firm posted $1.23 EPS. The company’s revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.